PhytoMedical Releases Preliminary Research Results For New Class of Diabetes Compounds
PRINCETON, N.J.--(BUSINESS WIRE)--Sep 4, 2007 - PhytoMedical Technologies, Inc. (OTCBB:PYTO) (FWB:ET6), today announced preliminary results from recent low-dosage animal studies of the Company's compounds for type-2 diabetes. The compounds being tested are synthetic versions of the isolated active metabolite derived from cinnamon and potentially represent an entirely new class of compounds for the treatment of type-2 diabetes.A previously published human study of type-2 diabetes patients showed that the isolated active metabolite of cinnamon, a Type A1 polyphenol, can actually lower blood sugar by an average of 18 to 29 percent and total cholesterol by 12 to 26 percent. PhytoMedical has synthetically recreated these compounds, which are now being tested in low dosage animal studies. Successful study outcomes will allow PhytoMedical to progress its research, with the eventual goal being to file for an Investigational New Drug application with the FDA which, if approved, will allow the Company to initiate Phase 1 human studies.
To evaluate the anti-diabetic effects of the new compounds, diabetes-induced male mice were fed ad libitum and administered low doses of several new PhytoMedical diabetes compounds. Despite low dosage, results of blood glucose and glucose tolerance tests showed activity comparable to what would be seen from already approved diabetes compounds.
"Our preliminary results of recent animal studies mark a major milestone in our product development pathway and lend credence to the platform from which our synthesized compounds are designed," stated Mr. Greg Wujek, President and CEO of PhytoMedical Technologies, Inc. "Our goal is to further evaluate our compounds at higher doses and continue to move closer to our Investigational New Drug application with the Food and Drug Administration."
PhytoMedical's Synthetic Compounds: Modeling 'Natural' Success
PhytoMedical is developing an entirely new, innovative class of diabetes compounds that are patterned after polyphenols found in cinnamon, shown in numerous published studies to favorably affect type-2 diabetes.
A human study of type-2 diabetes patients published in Diabetes Care, a journal of the American Diabetes Association, showed that cinnamon-derived polyphenolic compounds can significantly lower blood sugar by an average of 18 to 29 percent, triglycerides (fatty acids in the blood) by 23 to 30 percent, LDL (or "bad") cholesterol by 7 to 27 percent and total cholesterol by 12 to 26 percent. Changes in HDL ("good") cholesterol were not significant. Most importantly, no side effects were reported in the study.
Subsequently, an independent three-year study of human patients carried out by the Universiti Teknologi Malaysia, reported similar findings related to lower blood sugar levels.
More recently, in animal studies, third-party research published in Diabetologia, the official journal of the European Association for the Study of Diabetes, have confirmed that cinnamon-derived compounds are able to significantly reduce blood glucose levels with no apparent side effects.
Despite widely-acknowledged benefits attributed to these compounds, they are often considered unsuitable for prolonged clinical or therapeutic application due to the general lack of consistency in dosage, potency, composition, and stability of natural-occurring compounds.
In response, PhytoMedical is working to create synthetic 'copies' of the natural molecule responsible for cinnamon's anti-diabetic effect.
About PhytoMedical Technologies, Inc.
PhytoMedical Technologies, Inc. (OTCBB: PYTO; Frankfurt Stock Exchange: ET6), together with its wholly owned subsidiaries, is a pharmaceutical company focused on research, development and commercialization of pharmaceutical products.
For additional information, please visit: www.PhytoMedical.com
To receive future press releases via email, please visit: http://www.phytomedical.com/Alerts-Index.asp
To view the full HTML text of this release, please visit: http://www.PhytoMedical.com/IR/PressReleases/20070904-1.html
Legal Notice Regarding Forward-Looking Statements
No statement herein should be considered an offer or a solicitation of an offer for the purchase or sale of any securities. This release contains forward-looking statements that are based upon current expectations or beliefs, as well as a number of assumptions about future events. Although the Company believes that the expectations reflected in the forward-looking statements and the assumptions upon which they are based are reasonable, it can give no assurance that such expectations and assumptions will prove to have been correct. Forward-looking statements, which involve assumptions and describe our future plans, strategies, and expectations, are generally identifiable by use of the words "may," "will," "should," "could," "expect," "anticipate," "estimate," "believe," "intend," or "project" or the negative of these words or other variations on these words or comparable terminology. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous factors and uncertainties, including but not limited to adverse economic conditions, intense competition, lack of meaningful research results, entry of new competitors and products, adverse federal, state and local government regulation, inadequate capital, unexpected costs and operating deficits, increases in general and administrative costs, termination of contracts or agreements, technological obsolescence of the Company's products, technical problems with the Company's research and products, price increases for supplies and components, litigation and administrative proceedings involving the Company, the possible acquisition of new businesses or technologies that result in operating losses or that do not perform as anticipated, unanticipated losses, the possible fluctuation and volatility of the Company's operating results, financial condition and stock price, losses incurred in litigating and settling cases, dilution in the Company's ownership of its business, adverse publicity and news coverage, inability to carry out research, development and commercialization plans, loss or retirement of key executives and research scientists, changes in interest rates, inflationary factors, and other specific risks. We currently have no commercial products intended to diagnose, treat, prevent or cure any disease. The statements contained in this press release regarding our on going research and development and the results attained by us to-date have not been evaluated by the Food and Drug Administration. There can be no assurance that further research and development, and /or whether clinical trial results, if any, will validate and support the results of our preliminary research and studies. Further, there can be no assurance that the necessary regulatory approvals will be obtained or that PhytoMedical will be able to develop commercially viable products on the basis of its technologies. In addition, other factors that could cause actual results to differ materially are discussed in the Company's most recent Form 10-QSB and Form 10-KSB filings with the Securities and Exchange Commission. These reports and filings may be inspected and copied at the Public Reference Room maintained by the U.S. Securities & Exchange Commission at 100 F Street, N.E., Washington, D.C. 20549. You can obtain information about operation of the Public Reference Room by calling the U.S. Securities & Exchange Commission at 1-800-SEC-0330. The U.S. Securities & Exchange Commission also maintains an Internet site that contains reports, proxy and information statements, and other information regarding issuers that file electronically with the U.S. Securities & Exchange Commission at http://www.sec.gov. The Company undertakes no obligation to publicly release the results of any revisions to these forward looking statements that may be made to reflect the events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.
Contact
PhytoMedical Technologies, Inc.
Mr. Greg Wujek, 800-611-3388
President & CEO
www.PhytoMedical.com
Clinical Trial Results Archive
2007: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2006: Dec
